Database/Guides/NAD+ (Nicotinamide Adenine Dinucleotide)
Longevity

NAD+ (Nicotinamide Adenine Dinucleotide)

Clinical Protocol Guide for Peptide Protocol Portal & Associated Longevity, Metabolic & Cognitive Applications

📋 Full Clinical Guide⬇ Download Guide🧮 Calculator
Dosing Reference
100mg vialIM · Brain + Mood
BAC Water
2mL
Amt / Unit
0.5mg/unit
Dose Range
50-100mg
Draw (units)
100-200 units
Frequency
Daily or 2x/week
Route
IM
ℹSingle dose not to exceed 250mg
500mg vialIM · Brain + Mood
BAC Water
2mL
Amt / Unit
2.5mg/unit
Dose Range
50-150mg
Draw (units)
20-60 units
Frequency
Daily or 2x/week
Route
IM
ℹSingle dose not to exceed 250mg
Clinical Use Cases
energylongevitycognitive functionDNA repairaddiction recovery
Clinical Guide
Open full guide →

1. Clinical Overview

Molecule: NAD+ (Nicotinamide Adenine Dinucleotide)

Class: Mitochondrial redox coenzyme • Master metabolic regulator • DNA repair cofactor • Sirtuin activator

Essential for: ATP production, mitochondrial function, cellular energy, DNA repair (PARP), sirtuin activation (SIRT1–7), stem-cell function, neuroprotection, circadian regulation, inflammatory modulation

Age-related decline: NAD+ drops up to 50% by age 40 and >70% by age 60 due to increased CD38, mitochondrial dysfunction, inflammatory stress, NAMPT decline, oxidative damage. Directly linked to fatigue, cognitive impairment, slowed metabolism, sarcopenia, immune aging, insulin resistance.

2. Mechanisms of Action

2.1 Mitochondrial ATP Production

NAD+/NADH cycling drives Complex I, electron transport chain, oxidative phosphorylation, ATP synthesis. More energy, better exercise tolerance, less fatigue.

2.2 Sirtuin Activation (SIRT1–7)

Sirtuins modulate DNA repair, autophagy, inflammation, mitochondrial biogenesis, longevity genes. NAD+ depletion impairs sirtuins; restoration reactivates longevity pathways.

2.3 PARP & DNA Repair

PARPs are NAD+-hungry enzymes. Low NAD+ = impaired DNA repair, genomic instability. Repletion enhances repair, reduces oxidative damage.

2.4 Neuroprotection

Supports axonal survival, myelin repair, neurotransmitter regulation, neuroinflammation reduction. Useful for cognitive decline, stress-related neuroinflammation, post-concussion recovery.

2.5 Metabolic Regulation

Enhances insulin sensitivity, mitochondrial fat oxidation, reduces visceral adiposity, normalizes metabolic flexibility.

2.6 Immune & Inflammatory

Reduces TNF-α, IL-6, NLRP3 inflammasome, oxidative stress. Supports healthier immune aging (immunosenescence reduction).

3. Evidence Summary

3.1 Longevity & Anti-Aging

Boosts sirtuin activity (SIRT1, SIRT3), mitochondrial quality control, DNA repair, reduced senescence, better stem-cell function.

3.2 Cognitive Support

Improved clarity, executive function, concentration, learning/memory, neuroplasticity. Brain fog, cognitive decline, concussion recovery.

3.3 Metabolic Enhancement

Increased fat oxidation, BMR, glucose tolerance, mitochondrial efficiency. Weight loss resistance, aging-related metabolic decline, PCOS.

3.4 Physical Performance

Improved ATP output, VO2 max potential, endurance, muscle recovery, tissue resilience.

3.5 Immunity & Inflammation

Suppresses pro-inflammatory cytokines, oxidative pathways, immune exhaustion patterns.

4. Oral NAD+ Protocol

Forms: NR (Nicotinamide Riboside) or NMN (Nicotinamide Mononucleotide)
Base: 500–1,000 mg/day, split AM + mid-afternoon
Performance: 1,000–1,500 mg/day
Longevity: 1,000 mg/day + sirtuin co-factors
Cycle: Continuous or 5-on/2-off

Synergistic Co-Factors

Resveratrol/pterostilbene (SIRT1), CoQ10, L-carnitine, R-lipoic acid, magnesium threonate (neural), REVIVE™

5. Injectable NAD+ Protocol (IV / IM)

5.1 IV NAD+

Standard: 250–500 mg IV, 45–90 min infusion, 1–2×/week × 4–8 weeks
High-Dose: 750–1,000 mg IV (addiction recovery, neurocognitive, anti-aging)
Maintenance: Every 2–4 weeks

5.2 IM NAD+

100–300 mg IM, 1–3×/week. For patients who cannot tolerate IV sensations.

6. Decision Tree — Route Selection

Longevity & cellular repair? → Oral + periodic IV

Cognitive enhancement? → Oral + IM/IV weekly × 4–8 weeks

Metabolic/weight loss? → Oral daily + SLU-PP-332 + 5-Amino-1MQ

Sensitive to stimulants? → NAD+ preferred (non-stimulant)

Rapid improvement? → IV protocol

Maintenance? → Oral + REVIVE™ combo

7. Integrated Archetypes

A — Longevity

NAD+ 500–1,000 mg/day + REVIVE™ + RECOVER™ (GHK-Cu + BPC-157) + Resveratrol/pterostilbene

B — Cognitive Optimization

Oral NAD+ daily + Weekly IM/IV × 4–6 weeks + REBALANCE™ for autonomic/cognitive support

C — Metabolic & Weight Loss

NAD+ daily + SLU-PP-332 (UCP-1) + 5-Amino-1MQ + REVIVE™ AM

D — Athletic Performance

Oral NAD+ + IV post-cycle weekly × 4 + RECOVER™ + Creatine + electrolytes + high-protein

8. Contraindications & Monitoring

Contraindications

  • Pregnancy / Lactation
  • Active cancer (case-by-case)
  • Severe liver failure
  • Uncontrolled arrhythmias (IV)

Monitoring

  • Energy levels, cognition, sleep
  • HR/BP during IV infusion
  • Glucose tolerance
  • Liver panel (high-dose IV)

Legal Disclaimer

This document is provided solely for educational and informational purposes. NAD+ and other compounds are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — NAD+ Clinical Reference Guide

Foundational Biochemistry
1. Imai, S., & Guarente, L. NAD+ and sirtuins in aging. Trends Cell Biol, 24(8), 464–471 (2014).
2. Verdin, E. NAD+ in aging, metabolism, neurodegeneration. Science, 350(6265), 1208–1213 (2015).
3. Ying, W. NAD+/NADH balance and survival. Antioxid Redox Signal, 10(2), 179–206 (2008).
4. Canto, C., & Auwerx, J. NAD+ biosynthesis pathways. J Biol Chem, 284(24), 15812–15817 (2009).
Mitochondrial Function & Redox
5. Gomes, A. P., et al. NAD+ decline induces mitochondrial dysfunction. Cell, 155(7), 1624–1638 (2013).
6. Chini, C. C. S., et al. NAD+ regulates mitochondrial biogenesis. Nat Rev Mol Cell Biol, 22(2), 119–141 (2021).
7. Amaral, A., et al. NAD+ and mitochondrial metabolism. Mol Metabolism, 52, 101320 (2021).
Sirtuins, PARPs & Longevity
8. Belenky, P., et al. NAD+ metabolism in health/disease. Cell, 134(6), 1092–1100 (2008).
9. Cantó, C., et al. NAD+ replenishment improves survival. Cell Metabolism, 17(6), 856–870 (2013).
10. Mouchiroud, L., et al. NAD+-sirtuin activation improves lifespan. Cell, 154(2), 430–441 (2013).
11. Fang, E. F., et al. NAD+ repletion extends lifespan. Science, 352(6292), 1436–1443 (2016).
Inflammation & Immunity
12. Minhas, P. S., et al. NAD+ depletion drives neuroinflammation. Nat Neurosci, 22(7), 1014–1028 (2019).
13. Gerner, R. R., et al. Inflammation-induced NAD+ consumption. Cell Reports, 29(7), 1931–1942 (2019).
14. Van Gool, F., et al. PARP overactivation and NAD+ depletion. Nat Med, 15(10), 1179–1186 (2009).
Neuroprotection & Cognition
15. Lautrup, S., et al. NAD+ in brain aging. Nat Rev Neurol, 15(11), 610–624 (2019).
16. Hou, Y., et al. NAD+ rescues cognitive decline. PNAS, 115(27), E6329–E6338 (2018).
17. Fang, E. F., et al. NAD+ in Alzheimer’s/Parkinson’s. Cell Metabolism, 30(1), 107–126 (2019).
Cardiometabolic Health
18. Yoshino, M., et al. NMN increases NAD+ in humans. Science, 372(6547), 1224–1229 (2021).
19. Trammell, S. A. J., & Brenner, C. NAD+ in metabolic health. Trends Endocrinol Metab, 24(8), 419–428 (2013).
20. Canto, C., et al. NAD+ enhances insulin sensitivity. Cell Metabolism, 17(6), 856–870 (2013).
Human Clinical Trials
21. Trammell, S. A. J., et al. Oral NR increases NAD+. Nat Commun, 7, 12948 (2016).
22. Martens, C. R., et al. NR improves vascular health. Nat Commun, 9, 1286 (2018).
23. Dellinger, R. W., et al. NR + pterostilbene reduces bio-age. Aging, 9(11), 2523–2540 (2017).
24. Elhassan, Y. S., et al. NMN elevates NAD+ in humans. Diabetologia, 62(9), 1574–1587 (2019).
25. Grant, R., et al. IV NAD+ in addiction/chronic fatigue. J Psychoactive Drugs, 53(3), 207–216 (2021).
Aging & Longevity
26. Rajman, L., et al. NAD+ boosting therapeutics. Cell Metabolism, 27(3), 529–547 (2018).
27. Chini, E. N., et al. NAD+ and sirtuins in longevity. Nat Rev Endocrinol, 17(9), 558–573 (2021).
28. Imai, S. NAD+ as master regulator of aging. Genes Dev, 33(15–16), 1127–1139 (2019).
Pharmacokinetics & Safety
29. Airhart, S. E., et al. NR pharmacokinetics and safety. PLOS ONE, 12(12), e0186459 (2017).
30. Conze, D. B., et al. NR chloride safety and dose-response. Sci Reports, 9, 9772 (2019).
31. Katsyuba, E., & Auwerx, J. NAD+ metabolism disturbances and safety. Cell Research, 30(4), 570–584 (2020).
🔒

Provider Access Required

Create a provider account to read the full clinical guide for NAD+ (Nicotinamide Adenine Dinucleotide).

Quick Links